HeartBeam, Inc. (BEAT)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch BEAT
See up to 3 months of BEAT. The 7-day demo opens the 1M and 3M ranges and puts BEAT on your watchlist.
Start 7-day demoLatest BEAT insider trades
- Richard Ferrari - DirectorOpen-market purchase$46K
Tim Cruickshank - OfficerOpen-market purchase$25K
About HeartBeam, Inc. (BEAT)
The SEC lists HeartBeam, Inc. under CIK 0001779372, in surgical and medical instruments and apparatus. It is grouped with Health Care companies on this site.
BEAT Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 17 | 4,481,245 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
BEAT insider transactions (Form 4)
3940 Form 4 filings on record, the earliest from Jul 1, 2025, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Willem Elfrink - Director | Grant or award | Restricted Stock Units | 93,750 | $0.00 | - | |
| Willem Elfrink - Director | Grant or award | Stock Option (right to buy) | 93,750 | $0.00 | - | |
| Richard Ferrari - Director | Grant or award | Restricted Stock Units | 125,000 | $0.00 | - | |
| Richard Ferrari - Director | Grant or award | Restricted Stock Units | 90,625 | $0.00 | - | |
| Richard Ferrari - Director | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
 Michael R. Jaff - Director | Grant or award | Restricted Stock Units | 93,750 | $0.00 | - | |
| Michael R. Jaff - Director | Grant or award | Restricted Stock Units | 37,500 | $0.00 | - | |
| Marga Ortigas-Wedekind - Director | Grant or award | Restricted Stock Units | 93,750 | $0.00 | - | |
| Marga Ortigas-Wedekind - Director | Grant or award | Stock Option (right to buy) | 81,250 | $0.00 | - | |
| Kenneth Warwick Nelson III - Director | Grant or award | Restricted Stock Units | 93,750 | $0.00 | - | |
| Kenneth Warwick Nelson III - Director | Grant or award | Restricted Stock Units | 31,250 | $0.00 | - | |
 Urioste George de - Director | Grant or award | Restricted Stock Units | 93,750 | $0.00 | - | |
| Urioste George de - Director | Grant or award | Stock Option (Right to Buy) | 93,750 | $0.00 | - | |
 Kenneth Harry Persen - Officer | Grant or award | Common Stock | 105,740 footnote F1 | $0.00 | - | |
| ||||||
| Tim Cruickshank - Officer | Grant or award | Common Stock | 167,760 footnote F1 | $0.00 | - | |
| ||||||
| Branislav Vajdic - Officer | Grant or award | Common Stock | 2,800,000 footnote F1 | $0.00 | - | |
| Branislav Vajdic - Officer | Grant or award | Common Stock | 260,870 footnote F2 | $0.00 | - | |
| ||||||
| Richard Ferrari - Director | Open-market purchase | Common Stock | 57,500 | $0.80 | $46K | |
| Tim Cruickshank - Officer | Open-market purchase | Common Stock | 31,250 footnote F1 | $0.80 | $25K | |
| ||||||
| Willem Elfrink - Director | Open-market purchase | Common Stock | 187,500 footnote F1 | $0.80 | $150K | |
| ||||||
| Michael R. Jaff - Director | Open-market purchase | Common Stock | 31,250 footnote F1 | $0.80 | $25K | |
| ||||||
| Branislav Vajdic - Director | Open-market purchase | Common Stock | 31,250 footnote F1 | $0.80 | $25K | |
| ||||||
| Richard Ferrari - Director | Open-market purchase | Common Stock | 62,500 footnote F1 | $0.80 | $50K | |
| ||||||
 Robert Paul Eno - Officer | Open-market purchase | Common Stock | 12,500 footnote F1 | $0.80 | $10K | |
| ||||||
| Marga Ortigas-Wedekind - Director | Open-market purchase | Common Stock | 25,000 footnote F1 | $0.80 | $20K | |
| ||||||
 Mark E. Strome - Director | Open-market purchase | Common Stock | 750,000 footnote F1 | $0.80 | $600K | |
| ||||||
| Marga Ortigas-Wedekind - Director | Grant or award | Common Stock(right to buy) | 44,827 | $0.00 | - | |
| Richard Ferrari - Director | Grant or award | Common Stock | 50,000 | $0.00 | - | |
| Mark E. Strome - 10% Owner | Grant or award | Common Stock (right to buy) | 41,380 | $0.00 | - | |
| Michael R. Jaff - Director | Grant or award | Common Stock | 20,689 | $0.00 | - | |
| Branislav Vajdic - Officer | Grant or award | Common Stock (right to buy) | 61,932 | $0.00 | - | |
| Tim Cruickshank - Officer | Grant or award | Common Stock (right to buy) | 53,104 | $0.00 | - | |
| Willem Elfrink - Director | Grant or award | Common Stock (right to buy) | 51,724 | $0.00 | - | |
| Kenneth Warwick Nelson III - Director | Grant or award | Common Stock | 17,241 | $0.00 | - | |
| Urioste George de - Director | Grant or award | Common Stock (right to buy) | 51,724 | $0.00 | - | |
| Robert Paul Eno - Officer | Grant or award | Common Stock (right to buy) | 55,172 | $0.00 | - | |
| Mark E. Strome - 10% Owner | Open-market sale | Common Stock | 250,000 | $3.58 | $895K | |
| Urioste George de - Director | Open-market sale | Common Stock | 23,961 | $3.68 footnote F1 | $88K | |
| Urioste George de - Director | Open-market sale | Common Stock | 33,185 | $2.83 footnote F1 | $94K | |
| ||||||
Item 1.01, 9.01
Item 5.02, 9.01
Item 5.07
Item 3.01
BEAT insider trading FAQ
What is the latest insider trade for BEAT?
HeartBeam, Inc. (BEAT) had 9 insider filings in the last 90 days, with the most recent on 2026-10-09. The full record for BEAT runs to 40 Form 4 filings, the earliest from 2025-07-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying BEAT stock?
No insider purchases of BEAT were filed in the last 90 days. 9 purchases are on record for this company.
How many insiders are selling BEAT stock?
No insider sales of BEAT were filed in the last 90 days. 3 sales are on record for this company.
Where can I see BEAT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects BEAT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Willem Elfrink view on EDGAR
- - Richard Ferrari view on EDGAR
- - Michael R. Jaff view on EDGAR
- - Marga Ortigas-Wedekind view on EDGAR
- - Kenneth Warwick Nelson III view on EDGAR
- - Urioste George de view on EDGAR
- - Kenneth Harry Persen view on EDGAR
- - Tim Cruickshank view on EDGAR
- - Branislav Vajdic view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where BEAT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow BEAT with a 7-day demo
- BEAT on your watchlist
- Every BEAT Form 4 filing on record
- Up to 3 months of BEAT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
